WuXi AppTec Co., Ltd.

HKSE 2359.HK

WuXi AppTec Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2023: 13.04%

WuXi AppTec Co., Ltd. Return on Assets (ROA) is 13.04% for the year ending December 31, 2023, a -4.29% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

WuXi AppTec Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2022 was 13.62%, a 47.35% change year over year.
WuXi AppTec Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2021 was 9.25%, a 44.59% change year over year.
WuXi AppTec Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2020 was 6.39%, a 0.82% change year over year.
WuXi AppTec Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2019 was 6.34%, a -36.40% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

HKSE: 2359.HK

WuXi AppTec Co., Ltd.

CEO	Dr. Ge Li Ph.D.
IPO Date	Dec. 13, 2018
Location	China
Headquarters	288 Fute Zhong Road
Employees	41,116
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

Key trends

Past 5 years